- Home
- IOR vs PROK Comparison
IOR vs PROK Comparison
Compare IOR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- PROK
- Stock Information
- Founded
- IOR 1984
- PROK 2015
- Country
- IOR United States
- PROK United States
- Employees
- IOR N/A
- PROK N/A
- Industry
- IOR Real Estate Investment Trusts
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IOR Real Estate
- PROK Health Care
- Exchange
- IOR Nasdaq
- PROK Nasdaq
- Market Cap
- IOR 72.8M
- PROK 85.5M
- IPO Year
- IOR N/A
- PROK N/A
- Fundamental
- Price
- IOR $18.64
- PROK $3.29
- Analyst Decision
- IOR
- PROK Buy
- Analyst Count
- IOR 0
- PROK 5
- Target Price
- IOR N/A
- PROK $6.25
- AVG Volume (30 Days)
- IOR 497.0
- PROK 37.8M
- Earning Date
- IOR 08-07-2025
- PROK 08-08-2025
- Dividend Yield
- IOR N/A
- PROK N/A
- EPS Growth
- IOR N/A
- PROK N/A
- EPS
- IOR 1.10
- PROK N/A
- Revenue
- IOR N/A
- PROK $306,000.00
- Revenue This Year
- IOR N/A
- PROK $85.21
- Revenue Next Year
- IOR N/A
- PROK N/A
- P/E Ratio
- IOR $17.00
- PROK N/A
- Revenue Growth
- IOR N/A
- PROK N/A
- 52 Week Low
- IOR $15.69
- PROK $0.46
- 52 Week High
- IOR $19.69
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- IOR 51.09
- PROK 60.03
- Support Level
- IOR $18.02
- PROK $2.80
- Resistance Level
- IOR $18.89
- PROK $4.05
- Average True Range (ATR)
- IOR 0.18
- PROK 1.11
- MACD
- IOR -0.02
- PROK -0.07
- Stochastic Oscillator
- IOR 41.34
- PROK 37.15
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.